SBH
HRMY icon

Segall Bryant & Hamill’s Harmony Biosciences HRMY Stock Holding History

Segall Bryant & Hamill’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Hold
30,059
– – 0.01% 534
2026
Q1 		$842K Buy
30,059
+11,841
+65% +$388K 0.01% 528
2025
Q4 		$682K Buy
+18,218
New +$599K 0.01% 532

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Segall Bryant & Hamill's HRMY Position: Q2 2026 in Review

Segall Bryant & Hamill held its Harmony Biosciences (HRMY) position steady in Q2 2026 at 30,059 shares worth $1.09M. The position accounts for 0.01% of the portfolio, ranked #534.

Segall Bryant & Hamill first reported a position in HRMY in Q4 2025 and has held it in 3 quarters since. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Segall Bryant & Hamill held 30,059 shares of Harmony Biosciences worth $1.09M as of Q2 2026.
  • Segall Bryant & Hamill left its Harmony Biosciences share count unchanged in Q2 2026.
  • Harmony Biosciences made up 0.01% of Segall Bryant & Hamill's portfolio in Q2 2026, its #534 holding.
  • Segall Bryant & Hamill first reported a position in Harmony Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.